NOVO-NORDISK A/S-SPONS ADR (NVO) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:NVO - US6701002056 - ADR
NVO Key Statistics, Chart & Performance
The current stock price of NVO is 62.33 USD. In the past month the price increased by 30.48%. In the past year, price decreased by -20.79%.
NVO Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NVO. When comparing the yearly performance of all stocks, NVO is a bad performer in the overall market: 71.9% of all stocks are doing better.
NVO Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NVO. While NVO belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
NVO Financial Highlights
Over the last trailing twelve months NVO reported a non-GAAP Earnings per Share(EPS) of 3.63. The EPS increased by 10.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.88% | ||
| ROA | 20.26% | ||
| ROE | 61.08% | ||
| Debt/Equity | 0.52 |
NVO Forecast & Estimates
32 analysts have analysed NVO and the average price target is 63.79 USD. This implies a price increase of 2.35% is expected in the next year compared to the current price of 62.33.
For the next year, analysts expect an EPS growth of 4.79% and a revenue growth 7.98% for NVO
NVO Ownership
NVO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.31B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About NVO
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880 DK
CEO: Lars Fruergaard Jorgensen
Employees: 78554
Phone: 4544448888
NOVO-NORDISK A/S-SPONS ADR / NVO FAQ
Can you describe the business of NOVO-NORDISK A/S-SPONS ADR?
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
What is the stock price of NOVO-NORDISK A/S-SPONS ADR today?
The current stock price of NVO is 62.33 USD. The price increased by 9.12% in the last trading session.
What is the dividend status of NOVO-NORDISK A/S-SPONS ADR?
NOVO-NORDISK A/S-SPONS ADR (NVO) has a dividend yield of 0.46%. The yearly dividend amount is currently 1.55.
What is the ChartMill rating of NOVO-NORDISK A/S-SPONS ADR stock?
NVO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What do analysts say about NOVO-NORDISK A/S-SPONS ADR (NVO) stock?
32 analysts have analysed NVO and the average price target is 63.79 USD. This implies a price increase of 2.35% is expected in the next year compared to the current price of 62.33.
Can you provide the growth outlook for NOVO-NORDISK A/S-SPONS ADR?
The Revenue of NOVO-NORDISK A/S-SPONS ADR (NVO) is expected to grow by 7.98% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for NOVO-NORDISK A/S-SPONS ADR?
NOVO-NORDISK A/S-SPONS ADR (NVO) has a market capitalization of 276.96B USD. This makes NVO a Mega Cap stock.